Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06749899 | QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. | recruiting | Phase 3 | 580 | Sun Yat-Sen University Cancer CenterOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT05439278 | Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma | recruiting | Phase 3 | 178 | Severance HospitalOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06972641 | Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation | recruiting | Phase 2 / Phase 3 | 126 | Ruijin HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT03201861 | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | recruiting | Phase 3 | 762 | RenJi HospitalOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05502900 | Adjuvant Melatonin for Uveal Melanoma(AMUM) | recruiting | Phase 3 | 100 | Gustav StalhammarOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06332274 | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease(UMBRELLA) | recruiting | Phase 3 | 717 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06028737 | Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer(OCTASUR) | recruiting | Phase 2 / Phase 3 | 150 | Ukrainian Society of Clinical OncologyOTHER | 2 | May 6, 2025 | clinicaltrials |
| NCT06958627 | The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study(any) | recruiting | Phase 2 / Phase 3 | 964 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis(LIVERATION) | recruiting | Phase 3 | 471 | Can-Fite BioPharmaINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT05342194 | Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study | recruiting | Phase 3 | 480 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06912698 | Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma | recruiting | Phase 3 | 342 | Hai-Qiang Mai,MD,PhDOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT03592472 | A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | recruiting | Phase 3 | 413 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 6 | Apr 13, 2025 | clinicaltrials |
| NCT06196736 | A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer | recruiting | Phase 3 | 432 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06926543 | Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy(CONCERT) | recruiting | Phase 3 | 858 | Dr. Tabassum WadasadawalaOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06355427 | The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma(FAPIChol) | recruiting | Phase 2 / Phase 3 | 81 | Mara Veenstra, MDOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06752239 | Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC(PROTECT-NPC) | recruiting | Phase 3 | 474 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT01785420 | Pre Operative Trastuzumab in Operable Breast Cancer | recruiting | Phase 3 | 1,100 | Dr Rajendra A. BadweOTHER_GOV | 1 | Apr 9, 2025 | clinicaltrials |
| NCT03903835 | ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer(ProBio) | recruiting | Phase 3 | 750 | Karolinska InstitutetOTHER | 4 | Apr 9, 2025 | clinicaltrials |
| NCT06829459 | A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs | recruiting | Phase 3 | 350 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT03643276 | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | recruiting | Phase 3 | 5,000 | Martin SchrappeOTHER | 8 | Apr 6, 2025 | clinicaltrials |
| NCT06493552 | Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors | recruiting | Phase 2 / Phase 3 | 700 | Vasgene Therapeutics, IncINDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06907602 | Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma(ONTRESCC) | recruiting | Phase 2 / Phase 3 | 120 | Peking Union Medical College HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05255302 | De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction(DIAL) | recruiting | Phase 2 / Phase 3 | 1,360 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT03671044 | A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients | recruiting | Phase 3 | 657 | Jina Pharmaceuticals Inc.INDUSTRY | 2 | Mar 21, 2025 | clinicaltrials |
| NCT04513639 | The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study | recruiting | Phase 2 / Phase 3 | 176 | Oslo University HospitalOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05899465 | Perioperative Treatment With Tranexamic Acid in Melanoma(PRIME) | recruiting | Phase 3 | 1,204 | University of AarhusOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06879379 | KPD Consolidation After ASCT in NDMM Patients | recruiting | Phase 2 / Phase 3 | 202 | Peking University People's HospitalOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04314219 | Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients(PTCy-PMAT) | recruiting | Phase 3 | 264 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04996017 | Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)(AtezoMeso) | recruiting | Phase 3 | 162 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06095154 | CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 474 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05489289 | A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection | recruiting | Phase 3 | 570 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05595447 | Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma | recruiting | Phase 2 / Phase 3 | 20 | Hospital Regional de Alta Especialidad del BajioOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06617416 | A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC | recruiting | Phase 3 | 560 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT03895359 | Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma(TACE) | recruiting | Phase 3 | 128 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT04460352 | Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer(NEEDS) | recruiting | Phase 3 | 1,020 | Karolinska University HospitalOTHER | 5 | Mar 6, 2025 | clinicaltrials |
| NCT06170489 | A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) | recruiting | Phase 3 | 185 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT05955924 | Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial(SPRINTR) | recruiting | Phase 3 | 396 | Women's College HospitalOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06836492 | A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors. | recruiting | Phase 3 | 300 | Yizhuo ZhangOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT02923011 | Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas | recruiting | Phase 3 | 56 | Matthew BucknorOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06696794 | Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients | recruiting | Phase 3 | 180 | Shaogang WangOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT05991908 | Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies | recruiting | Phase 3 | 222 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06361329 | Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL | recruiting | Phase 3 | 81 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06830421 | Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients(PRIMA-CNS) | recruiting | Phase 3 | 340 | University Hospital FreiburgOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05737303 | Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer | recruiting | Phase 3 | 538 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06782412 | Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types(FAPIDO) | recruiting | Phase 2 / Phase 3 | 109 | KU LeuvenOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06802718 | Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia | recruiting | Phase 3 | 96 | Peking University People's HospitalOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06492395 | Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT | recruiting | Phase 3 | 178 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05601700 | Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)(LEPRE) | recruiting | Phase 3 | 132 | Ente Ospedaliero Ospedali GallieraOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06791005 | A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer. | recruiting | Phase 3 | 400 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 22, 2025source: clinicaltrials